© 2021 MJH Life Sciences™ and Pharmaceutical Executive. All rights reserved.
Barbara Ryan
Articles
Adding More Context to Biotech Headwinds
When was the last time a big pharma’s shares massively outperformed a biotech index YTD? Hint: You likely weren’t around.
Biotech Capital Markets Continue to Underperform
But could there be a shift in momentum?
Today’s Accelerated Pace of Innovation: Can We Afford It?
A remarkable run indeed, but cost questions can’t be ignored.
After Blowout 2020, Biotech Worst Performing Sector YTD
What are the reasons behind the slump and what does the future hold?
How Does it Feel When You Literally Can Change the World?
Adding context to Pfizer’s orbit-busting, first-quarter earnings.
Biopharma has Wind at its Back—Are Storm Clouds on Horizon?
More capital gains and the potential strains for rest of 2021.
Biopharma’s Reputation Gets a Well-Earned Shot in the Arm
Amid vaccine heroics, its complex story may finally be resonating.
The Best and the Worst on Display in Vaccine Effort
Dueling paths leave market fortunes uncertain.
JPM Conference Goes Virtual: What Will it Mean?
Tone still set on the market catalysts to look for in 2021.
For Investors, ’Tis the Season to be Grateful
Vaccine strides, likely pricing impasse point to optimism for 2021.